Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL242735 | 1.00 | ADORA2A (0.47) | ADORA2AADORA3HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL243065 | 0.92 | ADORA2A (0.52) | ADORA2AADORA3HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL242523 | 0.91 | ADORA2A (0.44) | ADORA2AADORA3HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL242739 | 0.91 | ADORA2A (0.44) | ADORA2AADORA3 | |
| Trifluoroacetic Acid SCHEMBL241766 | 0.91 | ADORA2A (0.44) | ADORA2AADORA3 | |
| Trifluoroacetic Acid SCHEMBL294573 | 0.90 | ADORA2A (0.43) | ADORA2AADORA3HRH4HRH3 | |
| SCHEMBL242736 | 0.90 | ADORA2A (0.41) | ADORA2AADORA3HRH4HRH3 | |
| SCHEMBL291809 | 0.90 | ADORA2A (0.41) | ADORA2AADORA3HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL293885 | 0.89 | ADORA2A (0.44) | ADORA2AADORA3HRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL293888 | 0.89 | ADORA2A (0.44) | ADORA2AADORA3HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |